Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2916 Plus Chemotherapy in Metastatic Pancreatic Cancer
NCT06962267Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2916, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Apr 2025; status: recruiting.
02
Drugs
TQB2916
Beyond the preview
Go deeper on NCT06962267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962267.